Presentations and films
2025

CPL’36 Unlocking New Possibilities in LiDTreatment – Phase 2 Top-Line Results
2024

Strong Proof-of-Concept Data from Phase 2 Trial of PDE10A Inhibitor (CPL’36)
2022

Investor's teleconference Y2022

Presentation Q3 2022

Investor's teleconference 1Q 2022
2021

Investor's teleconference

Capital Markets Day - 21.04.2021
Transcript >
Watch full CMD webcast >
Corporate deck >
Watch KOL's session >
Watch Corporate session >

Celon Pharma Announces Positive Falkieri Phase II Results in Treatment-Resistant Bipolar Depression

Shareholders of Celon Pharma S.A. On February 16, 2021, they will decide to authorize the Management Board to increase the share capital within the authorized capital by issuing new shares.